Key Highlights

  • GSK is opening a new chapter.
  • After nearly a decade with Emma Walmsley at the helm — a period that saw the demerger of consumer-health Business Haleon and a rebuilding of the pipeline — the FTSE 100 pharmaceutical group is transitioning to new leader...
  • GSK reported second-quarter sales up 5% to more than £8.4bn, with core operating profit up 7% and core Earnings Per Share up 9%.
  • Specialty medicines led the way with 14% growth, vaccines rose 8%, and the HIV business, ViiV, grew 10%, helped by Cabenuva up 33% and Apretude up 39%.

GSK is opening a new chapter. After nearly a decade with Emma Walmsley at the helm — a period that saw the demerger of consumer-health business Haleon and a rebuilding of the pipeline — the FTSE 100 pharmaceutical group is transitioning to new Leadership under Luke Miels, its long-serving commercial chief. The handover matters because GSK has spent years trailing rivals such as AstraZeneca on growth and valuation, and the incoming era is being judged on whether it can close that gap. The second-quarter results published on 28 July gave the new chapter an encouraging backdrop: growth across specialty medicines and vaccines, and an upgraded ambition for the end of the decade.

The quarter in numbers

GSK reported second-quarter sales up 5% to more than £8.4bn, with core operating profit up 7% and core earnings per share up 9%. Specialty medicines led the way with 14% growth, vaccines rose 8%, and the HIV business, ViiV, grew 10%, helped by Cabenuva up 33% and Apretude up 39%. General medicines fell 9%. Net Debt rose to around £22bn following the Acquisition of Nuvalent, an oncology deal that adds to the pipeline but carries interest costs of roughly £160m, a reminder that GSK is buying growth as well as developing it in house.

Building a growth engine

The strategy is to reshape GSK into a faster-growing, innovation-led business. Blenrep is leading new patient starts in second-line multiple myeloma in the UK, Nucala is gaining share in chronic obstructive pulmonary disease, and management is accelerating the pipeline with more than 20 Phase III starts planned in 2026. GSK raised its long-term ambition to more than £40bn in sales by 2031, and launched an 'Accelerate Growth' programme targeting £1.9bn of annual cost savings by 2029 to fund reinvestment and protect margins. Oncology, rebuilt largely from scratch after GSK sold much of its cancer portfolio in 2015, is central to that ambition.

Guidance and finances

On guidance, GSK nudged its 2026 outlook for sales and operating profit towards the upper half of the range, while trimming the EPS view to the lower half because of the Nuvalent financing costs. Cash generation of £4.3bn in the period and a £1bn improvement in free Cash Flow underpin the Dividend and reinvestment. Management said margins should be stable to improving even through the loss of exclusivity on dolutegravir, the key HIV Franchise whose patents represent a looming challenge and one of the most important variables in the group's medium-term forecasts. The Nuvalent-related rise in Leverage is modest against GSK's cash generation, but it narrows the room for further large deals.

Risks to weigh

The risks are significant. GSK faces Patent cliffs, most notably on its HIV portfolio, that the pipeline must offset in the coming years. Late-stage clinical failures could dent the growth ambition; US drug-pricing pressure threatens margins; and the group carries ongoing litigation exposure, including historic Zantac-related claims that have periodically unsettled the shares. Integrating acquisitions such as Nuvalent adds execution and financing risk, and a rising net-debt position reduces flexibility if pipeline read-outs disappoint or if a major trial fails to deliver. Vaccine demand, particularly for respiratory products, can also prove lumpy from year to year, complicating the smooth growth trajectory the market is looking for from the group.

Outlook

The leadership handover to Luke Miels puts renewed emphasis on R&D productivity and commercial execution. Investors may watch the cadence of Phase III read-outs, the ramp of Blenrep and other launches, and how GSK manages the dolutegravir exclusivity transition. Success will be measured against AstraZeneca and other rivals whose valuations already reflect stronger growth, and a clean run of positive read-outs would do more than any strategy statement to re-rate the shares. The central question is whether the strengthened pipeline can turn GSK into the faster-growing pharma the market has long wanted to see.